학술논문

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Document Type
Article
Source
In: The Lancet. (The Lancet, 24 - 30 June 2017, 389(10088):2492-2502)
Subject
Language
English
ISSN
1474547X
01406736